The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Proflavine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Proflavine inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
Proflavine inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]
Aminacrine results in decreased phosphorylation of H2AX protein [Aminacrine results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]
[Aminacrine results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; Aminacrine inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]
[Acridine Orange binds to Platinum Compounds] which results in increased expression of GSTP1 mRNA; [Acridine Orange binds to Platinum] which results in increased expression of GSTP1 mRNA
[Acridine Orange binds to Platinum Compounds] which results in increased expression of GSTP1 mRNA; [Acridine Orange binds to Platinum] which results in increased expression of GSTP1 mRNA
Acridines analog inhibits the reaction [CYP1A2 protein results in increased oxidation of vadimezan] Acridines analog results in decreased activity of CYP1A2 protein
Amsacrine results in decreased expression of BCL2L1 protein [[Amsacrine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; [[Amsacrine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; ELAVL1 protein inhibits the reaction [Amsacrine results in decreased expression of BCL2L1 mRNA]; ELAVL1 protein inhibits the reaction [Amsacrine results in increased degradation of BCL2L1 mRNA]
Amsacrine results in decreased expression of ELAVL1 protein [[Amsacrine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; [[Amsacrine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; [Amsacrine results in increased expression of MIR22] which results in decreased expression of ELAVL1 mRNA; Amsacrine results in decreased expression of and results in decreased stability of ELAVL1 mRNA; ELAVL1 protein inhibits the reaction [Amsacrine results in decreased expression of BCL2L1 mRNA]; ELAVL1 protein inhibits the reaction [Amsacrine results in increased degradation of BCL2L1 mRNA]; GLX351322 inhibits the reaction [Amsacrine results in decreased expression of ELAVL1 protein]
Amsacrine results in increased phosphorylation of H2AX protein ATM protein promotes the reaction [Amsacrine results in increased phosphorylation of H2AX protein]
MAP2K1 protein inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK1 protein]; MAP2K1 protein inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK3 protein]; MAP2K1 protein inhibits the reaction [Amsacrine results in increased expression of MIR22 protein]
[[Amsacrine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; GLX351322 inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK1 protein]; MAP2K1 protein inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK1 protein]; MitoTEMPO inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK1 protein]
Amsacrine results in increased activity of MAPK12 protein MAPK12 protein affects the susceptibility to Amsacrine [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Amsacrine; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Amsacrine
Amsacrine results in decreased phosphorylation of MAPK3 protein [[Amsacrine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; GLX351322 inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK3 protein]; MAP2K1 protein inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK3 protein]; MitoTEMPO inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK3 protein]
Amsacrine results in increased expression of MIR22 [Amsacrine results in increased expression of MIR22] which results in decreased expression of ELAVL1 mRNA; MAP2K1 protein inhibits the reaction [Amsacrine results in increased expression of MIR22 protein]
Amsacrine results in increased expression of NOX4 protein Amsacrine results in increased expression of and results in decreased degradation of NOX4 mRNA; SIDT2 protein promotes the reaction [Amsacrine results in increased expression of NOX4 mRNA]; SIDT2 protein promotes the reaction [Amsacrine results in increased expression of NOX4 protein]
SIDT2 protein promotes the reaction [Amsacrine results in decreased expression of MIR25 protein]; SIDT2 protein promotes the reaction [Amsacrine results in increased expression of NOX4 mRNA]; SIDT2 protein promotes the reaction [Amsacrine results in increased expression of NOX4 protein] Amsacrine results in increased expression of SIDT2 protein
[EGF protein results in decreased expression of TOP2A protein] which results in decreased susceptibility to Amsacrine; [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Amsacrine; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Amsacrine TOP2A protein modified form affects the susceptibility to Amsacrine TOP2A gene mutant form results in decreased susceptibility to Amsacrine; TOP2A protein mutant form results in decreased susceptibility to Amsacrine
Amsacrine analog results in increased activity of TP53 protein Amsacrine results in increased glutathionylation of TP53 protein Amsacrine results in increased stability of and results in increased activity of TP53 protein Amsacrine results in increased expression of TP53 protein
Ethacridine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Ethacridine inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
[Pyruvic Acid co-treated with Uridine co-treated with Ethidium] inhibits the reaction [Rotenone inhibits the reaction [arsenite results in increased expression of ERO1A protein]]
Ethidium inhibits the reaction [sodium arsenate results in increased expression of IL1A protein]; Ethidium inhibits the reaction [tributyltin results in increased expression of IL1A protein]
1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A1 protein results in increased uptake of Ethidium]; Cimetidine inhibits the reaction [SLC22A1 protein results in increased uptake of Ethidium]; Quinine inhibits the reaction [SLC22A1 protein results in increased uptake of Ethidium]; Tetraethylammonium inhibits the reaction [SLC22A1 protein results in increased uptake of Ethidium] SLC22A1 protein affects the uptake of Ethidium
SLC22A2 protein affects the uptake of Ethidium 1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A2 protein results in increased uptake of Ethidium]; Cimetidine inhibits the reaction [SLC22A2 protein results in increased uptake of Ethidium]; Ethidium inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Quinine inhibits the reaction [SLC22A2 protein results in increased uptake of Ethidium]; Tetraethylammonium inhibits the reaction [SLC22A2 protein results in increased uptake of Ethidium]
SLC22A3 protein results in increased uptake of Ethidium 1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A3 protein results in increased uptake of Ethidium]; Cimetidine inhibits the reaction [SLC22A3 protein results in increased uptake of Ethidium]; Quinine inhibits the reaction [SLC22A3 protein results in increased uptake of Ethidium]; Tetraethylammonium inhibits the reaction [SLC22A3 protein results in increased uptake of Ethidium]
narciclasine inhibits the reaction [Lipopolysaccharides results in increased degradation of and results in increased phosphorylation of NFKBIA protein]
narciclasine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; narciclasine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
phenanthridone results in increased expression of H2AX protein modified form Acetylcysteine inhibits the reaction [phenanthridone results in increased expression of H2AX protein modified form]; TXNRD1 protein inhibits the reaction [phenanthridone results in increased expression of H2AX protein modified form]
phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA] phenanthridone results in decreased expression of IFNG mRNA
phenanthridone results in decreased expression of IL2 mRNA phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]
phenanthridone results in decreased activity of PARP1 protein [eprenetapopt co-treated with phenanthridone] results in increased cleavage of PARP1 protein
phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA] phenanthridone analog inhibits the reaction [endotoxin, Escherichia coli results in increased expression of TNF protein] phenanthridone results in decreased expression of TNF mRNA
TXNRD1 protein inhibits the reaction [phenanthridone results in increased expression of H2AX protein modified form] phenanthridone results in decreased expression of TXNRD1 mRNA; phenanthridone results in decreased expression of TXNRD1 protein
Propidium binds to and results in decreased activity of ACHE protein; Propidium promotes the reaction [Dichlorvos results in increased phosphorylation of ACHE protein]; Propidium promotes the reaction [haloxon results in increased phosphorylation of ACHE protein]; Propidium promotes the reaction [Paraoxon results in increased phosphorylation of ACHE protein] Propidium results in decreased activity of ACHE protein
ABCB1 protein results in increased transport of Quinacrine Elacridar inhibits the reaction [ABCB1 protein results in increased transport of Quinacrine]
BAX protein results in increased susceptibility to Quinacrine Quinacrine results in increased expression of BAX mRNA 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in increased expression of BAX mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in increased expression of BAX protein]; BTRC protein inhibits the reaction [Quinacrine results in increased expression of BAX protein]; mithramycin A inhibits the reaction [Quinacrine results in increased expression of BAX mRNA]; mithramycin A inhibits the reaction [Quinacrine results in increased expression of BAX protein]; Quinacrine promotes the reaction [SP1 protein binds to BAX promoter]; Quinacrine results in increased expression of and affects the localization of BAX protein
Quinacrine results in decreased expression of BTRC protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in decreased expression of BTRC protein]; BTRC protein inhibits the reaction [Quinacrine results in increased expression of BAX protein]; BTRC protein inhibits the reaction [Quinacrine results in increased expression of SP1 protein]; FOXP3 protein affects the reaction [Quinacrine results in decreased expression of BTRC protein]; MIR183 mRNA affects the reaction [Quinacrine results in decreased expression of BTRC protein]; Quinacrine results in decreased expression of and results in decreased stability of BTRC mRNA
Quinacrine results in increased cleavage of CASP3 protein GSK3B protein affects the reaction [Quinacrine results in increased activity of CASP3 protein]
Quinacrine results in decreased expression of CCND1 protein GSK3B protein affects the reaction [Quinacrine results in decreased expression of CCND1 protein]
Quinacrine results in increased expression of CSNK1A1 protein GSK3B protein affects the reaction [Quinacrine results in increased expression of CSNK1A1 protein]
Quinacrine results in increased expression of FOXP3 mRNA; Quinacrine results in increased expression of FOXP3 protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in increased expression of FOXP3 mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in increased expression of FOXP3 protein]; FOXP3 protein affects the reaction [Quinacrine results in decreased expression of BTRC protein]; FOXP3 protein affects the reaction [Quinacrine results in increased expression of MIR183 mRNA]; FOXP3 protein affects the reaction [Quinacrine results in increased expression of SP1 protein]
Quinacrine results in decreased expression of GLI1 protein GSK3B protein affects the reaction [Quinacrine results in decreased expression of GLI1 protein]
Quinacrine results in increased expression of GSK3B mRNA GSK3B protein affects the reaction [Quinacrine results in decreased expression of CCND1 protein]; GSK3B protein affects the reaction [Quinacrine results in decreased expression of CTNNB1 protein]; GSK3B protein affects the reaction [Quinacrine results in decreased expression of GLI1 protein]; GSK3B protein affects the reaction [Quinacrine results in decreased expression of MYC protein]; GSK3B protein affects the reaction [Quinacrine results in increased activity of CASP3 protein]; GSK3B protein affects the reaction [Quinacrine results in increased expression of CSNK1A1 protein]; Quinacrine results in increased expression of and results in decreased phosphorylation of GSK3B protein
Quinacrine results in decreased phosphorylation of MAPK1 protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in decreased phosphorylation of MAPK1 protein]; Acetylcysteine inhibits the reaction [Quinacrine results in decreased phosphorylation of MAPK1 protein]
Quinacrine results in decreased phosphorylation of MAPK3 protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in decreased phosphorylation of MAPK3 protein]; Acetylcysteine inhibits the reaction [Quinacrine results in decreased phosphorylation of MAPK3 protein]
FOXP3 protein affects the reaction [Quinacrine results in increased expression of MIR183 mRNA]; MIR183 mRNA affects the reaction [Quinacrine results in decreased expression of BTRC protein]; MIR183 mRNA affects the reaction [Quinacrine results in increased expression of SP1 protein]
Quinacrine results in decreased expression of MYC protein GSK3B protein affects the reaction [Quinacrine results in decreased expression of MYC protein]
Quinacrine inhibits the reaction [PRL protein results in increased activity of OTC protein]; Quinacrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of OTC protein]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in increased expression of SP1 protein]; BTRC protein inhibits the reaction [Quinacrine results in increased expression of SP1 protein]; FOXP3 protein affects the reaction [Quinacrine results in increased expression of SP1 protein]; MIR183 mRNA affects the reaction [Quinacrine results in increased expression of SP1 protein]; Quinacrine promotes the reaction [SP1 protein binds to BAX promoter]; Quinacrine results in increased expression of and results in increased stability of SP1 protein
Quinacrine results in increased activity of TP53 protein Quinacrine affects the activity of TP53 protein Quinacrine results in increased stability of and results in increased activity of TP53 protein
Tacrine results in decreased activity of ACHE protein Tacrine inhibits the reaction [Scopolamine results in increased expression of ACHE protein] ALB protein affects the reaction [Tacrine results in decreased activity of ACHE protein] Tacrine analog results in decreased activity of ACHE protein; Tacrine results in decreased activity of ACHE protein
Tacrine inhibits the reaction [Staurosporine results in increased expression of BAX protein] Tacrine inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX mRNA]; Tacrine inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein]
[Tacrine co-treated with Scopolamine] results in increased expression of BDNF protein; Tacrine inhibits the reaction [Scopolamine results in decreased expression of BDNF protein]
Tacrine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] Tacrine results in increased expression of CHRNA4 protein Mecamylamine inhibits the reaction [Tacrine results in increased expression of CHRNA4 protein]
Tacrine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] Tacrine results in increased expression of CHRNB2 protein Mecamylamine inhibits the reaction [Tacrine results in increased expression of CHRNB2 protein]
Tacrine analog results in increased expression of CYP1A1 protein; Tacrine results in increased expression of CYP1A1 mRNA; Tacrine results in increased expression of CYP1A1 protein CYP1A1 protein affects the metabolism of Tacrine Tacrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
Chloroquine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]; Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]; Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]; NADP promotes the reaction [Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; Tacrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] Tacrine results in decreased activity of CYP1A2 protein CYP1A2 protein affects the metabolism of Tacrine
Tacrine analog results in increased expression of CYP3A2 protein; Tacrine results in increased expression of CYP3A2 protein CYP3A4 protein results in increased susceptibility to Tacrine
Tacrine inhibits the reaction [NQO1 protein results in increased reduction of 2,6-Dichloroindophenol] Tacrine results in decreased activity of NQO1 protein
Tacrine results in decreased activity of NQO2 protein Tacrine inhibits the reaction [NQO2 protein results in increased reduction of 2,6-Dichloroindophenol]; Tacrine inhibits the reaction [NQO2 protein results in increased reduction of amodiaquine quinoneimine]; Tacrine inhibits the reaction [NQO2 protein results in increased reduction of N-acetyl-4-benzoquinoneimine]; Tacrine inhibits the reaction [NQO2 protein results in increased reduction of thiazolyl blue]
Tacrine inhibits the reaction [SLC22A2 protein polymorphism results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Tacrine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
Tacrine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Tacrine inhibits the reaction [SLC47A1 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
Tacrine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA]; Tacrine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein]
browse the term
